Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
READ MORE...
Pneumagen initiates Phase 1 trial of Neumifil, a novel, intranasal pan anti-viral therapeutic for the prophylaxis and treatment of viral Respiratory Tract Infections
READ MORE...
Pneumagen Appoints New Head of Research to Expand its Anti-Viral Pipeline leveraging its Proprietary GlycoTarge™ Platform
READ MORE...
Pneumagen Announces Neumifil™ is Efficacious In an Established Model of COVID-19 Infection
READ MORE...
Pneumagen Announces £2.5m fundraising to advance universal treatment for viral respiratory infections into the clinic this year
READ MORE...
Pneumagen’s Neumifil for combating COVID-19 featured in SCRIP’s 10 to watch at BIO-Europe Digital
READ MORE...
Pneumagen Announces Scientific Advisory Board and Development Team Appointments
READ MORE...
Pneumagen Announces £4m fundraising and Commits to Clinical Trial Development for COVID-19
READ MORE...
Pneumagen Ltd’s Recent COVID-19 Data Covered by BBC’s “The Nine”
